, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study, The lancet Gastroenterology & hepatology, vol.2, pp.161-76, 2017.

, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study, GBD 2013 Mortality and Causes of Death Collaborators, vol.385, pp.117-71, 2013.

B. Simmons, J. Saleem, K. Heath, G. S. Cooke, and A. Hill, Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained Virological response, Clin Infect Dis, vol.61, pp.730-770, 2015.

J. Smith-palmer, K. Cerri, and W. Valentine, Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits, BMC Infect Dis, vol.15, p.19, 2015.

, European Association for the Study of the Liver. EASL recommendations on Treatment of Hepatitis C 2016, J Hepatol, vol.66, pp.153-94, 2017.

S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago et al., Telaprevir for retreatment of HCV infection, N Engl J Med, vol.364, pp.2417-2445, 2011.

F. Poordad, J. Mccone, J. Bacon, B. R. Bruno, S. Manns et al., Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, vol.364, pp.1195-206, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00867494

, European Association for the Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015, J Hepatol, vol.63, pp.199-236, 2015.

, European Association for the Study of the Liver. EASL recommendations on Treatment of Hepatitis C 2014, J Hepatol, vol.61, pp.373-95, 2014.

S. Iyengar, K. Tay-teo, S. Vogler, P. Beyer, S. Wiktor et al., Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis, PLoS Med, vol.13, p.1002032, 2016.

S. M. Lynch, W. Hepatitis, C. Virus, and A. Review, Of treatment guidelines, costeffectiveness, and access to therapy, Journal of clinical and translational hepatology, vol.4, pp.310-319, 2016.

G. Balasubramanian, S. Morampudi, P. Chhabra, A. Gowda, and B. Zomorodi, An overview of compassionate use programs in the European Union member states. Intractable & Rare Diseases Research, vol.5, pp.244-54, 2016.

, Ministère des Affaires sociales et de la Santé. Discours de Marisol TouraineJournée de lutte contre les hépatites virales, 2017.

. Haute-autorité-de-santé, Prise en charge de l'hépatite C par les médicaments anti-viraux à action directe (AAD), 2017.

. Haute-autorité-de-santé, Prise en charge de l'hépatite C par les médicaments anti-viraux à action directe, 2017.

, Prise en charge des personnes infectées par les virus de l'hépatite B ou de l'hépatite C. Rapport de recommandations, 2014.

, Professeur Daniel Dhumeaux et sous l'égide de l'ANRS et de l'AFEF, 2017.

H. Leleu, H. Razavi, C. Hézode, M. Blachier, and F. Roudot-thoraval, Modélisation de l'impact épidémiologique des nouveaux anti-viraux dans le traitement de l'hépatite C. Lille: 73èmes Journées de l'Association Française pour l'Etude du Foie (AFEF), 2013.

C. Pioche, C. Pelat, C. Larsen, J. C. Desenclos, J. Roustide et al., Estimation de la prévalence de l'hépatite C en population générale, France métropolitaine, Bull Epidemiol Hebd, pp.224-233, 2011.

C. Brouard, L. Strat, Y. Larsen, C. Jauffret-roustide, M. Lot et al., The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014, PLoS One, vol.10, p.126920, 2015.

M. D. Pauti, A. Tomasino, C. Mari, C. Mathieu, A. Kartner et al., Limiter les opportunités manquées de dépistage des hépatites B et C chez les migrants en situation de précarité : le programme de Médecins du Monde en France, Bull Epidemiol Hebd, pp.230-236, 2016.

C. Semaille, L. Strat, Y. Chiron, E. Chemlal, K. Valantin et al., Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy, Euro Surveill, vol.18, 2013.

L. Weill-barillet, J. Pillonel, C. Semaille, L. Leon, L. Strat et al., Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot, survey. Rev Epidemiol Sante Publique, vol.64, pp.301-313, 2011.

L. Leon, S. Kasereka, F. Barin, C. Larsen, L. Weill-barillet et al., Age-and time-dependent prevalence and incidence of hepatitis C virus infection in drug users in France, Epidemiol Infect, vol.2016, pp.1-13, 2004.

F. Santé-publique, Surveillance nationale de l'hépatite C à partir des pôles de référence volontaires, 2001.

G. Geri, M. Maynard, E. Rosenthal, H. Fontaine, K. Lacombe et al., Care of hepatitis C virus infection in France: modifications in three consecutive surveys between, Liver Int, vol.34, pp.1349-57, 1995.
URL : https://hal.archives-ouvertes.fr/hal-01917077

G. Moulis, M. Lapeyre-mestre, A. Palmaro, G. Pugnet, J. L. Montastruc et al., French health insurance databases: what interest for medical research, Rev Med Interne, vol.36, pp.411-418, 2015.

P. Tuppin, J. Rudant, P. Constantinou, C. Gastaldi-menager, A. Rachas et al., Value of a national administrative database to guide public decisions: from the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France, 2017.

. Haute-autorité-de-santé, Actes et prestations. Affection de longue durée, 2017.

, European Association of the Study of the Liver hepatitis C virus clinical practice guidelines, Liver Int, vol.32, issue.1, pp.2-8, 2011.

C. Hezode, P. Lebray, V. De-ledinghen, F. Zoulim, D. Martino et al., Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01784615

S. Pol, M. Bourliere, S. Lucier, C. Hezode, C. Dorival et al., Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients, J Hepatol, vol.66, pp.39-47, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01435007

, AFEF guidelines. Management of hepatitis C virus infection, 2015.

C. Hezode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim et al., Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access Programme (ANRS CO20CUPIC)-NCT01514890, J Hepatol, vol.59, pp.434-475, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01708037

R. Zimmermann, C. Kollan, P. Ingiliz, S. Mauss, D. Schmidt et al., Realworld treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, J Hepatol, vol.67, pp.15-22, 2017.

C. Dessauce, J. Rudant, A. Expert, P. Barthélemy, and B. Cadier, Les antiviraux à action directe (AAD) dans le traitement de l'hépatite C: retour sur 18 mois de prise en charge par l'Assurance Maladie. Points de repère, vol.44, pp.1-7, 2016.

C. Meffre, L. Strat, Y. Delarocque-astagneau, E. Dubois, F. Antona et al., Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors, J Med Virol, vol.82, pp.546-55, 2010.

P. Ingiliz, S. Christensen, T. Kimhofer, D. Hueppe, T. Lutz et al., Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-Monoinfected and HIV-HCV-Coinfected individuals: results from the German hepatitis C cohort (GECCO-01), Clin Infect Dis, vol.63, pp.1320-1324, 2016.

D. S. Fox, J. J. Mcginnis, I. Q. Tonnu-mihara, and J. S. Mccombs, Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration, J Gastroenterol Hepatol, vol.32, pp.1136-1178, 2017.

A. L. Mouterde, F. Bocquet, I. Fusier, P. Paubel, and C. Hepatitis, How has France limited the expenses related to new treatments?, Expert Rev Pharmacoecon Outcomes Res, vol.16, pp.655-662, 2016.

E. Delarocque-astagneau, C. Meffre, F. Dubois, C. Pioche, L. Strat et al., The impact of the prevention programme of hepatitis C over more than a decade: the French experience, J Viral Hepat, vol.17, pp.435-478, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00867912

P. Tuppin, S. Samson, N. Colinot, C. Gastaldi-menager, A. Fagot-campagna et al., Health care use by free complementary health insurance coverage beneficiaries in France in 2012, Rev Epidemiol Sante Publique, vol.64, pp.67-78, 2016.

S. Deuffic-burban, J. Boursier, V. Leroy, Y. Yazdanpanah, L. Castera et al., Are targeted treatment recommendations in chronic hepatitis C tailored to diagnostic methods of fibrosis?, J Hepatol, vol.66, pp.304-316, 2017.

M. Hellard, D. A. Rolls, R. Sacks-davis, G. Robins, P. Pattison et al., The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs, Hepatology, vol.60, pp.1861-70, 2014.

N. K. Martin, G. R. Foster, J. Vilar, S. Ryder, M. E. Cramp et al., HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact, J Viral Hepat, vol.22, pp.399-408, 2015.

, World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis, 2017.

, Prise en charge thérapeutique et suivi de l'ensemble des personnes infectées par le virus de l'hépatite C. Rapport de recommandations 2016, Sous la direction du Pr Daniel Dhumeaux. Sous l'égide de l'ANRS et du CNS et avec le concours de l'AFEF, 2017.

J. Bottero, C. Brouard, F. Roudot-thoraval, S. Deuffic-burban, P. Hofliger et al., French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV, Liver Int, vol.36, pp.1442-1451, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01299138